🇺🇸 FDA
Pipeline program

A study to compare two different aramchol formulations in healthy volunteers.

CGA23001

Phase 1 other active

Quick answer

A study to compare two different aramchol formulations in healthy volunteers. for Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis is a Phase 1 program (other) at Galmed Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Galmed Pharmaceuticals
Indication
Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis
Phase
Phase 1
Modality
other
Status
active

Clinical trials